Literature DB >> 26468534

Kaposi's Sarcoma-Associated Herpesvirus Reduces Cellular Myeloid Differentiation Primary-Response Gene 88 (MyD88) Expression via Modulation of Its RNA.

Amy Lingel1, Erica Ehlers1, Qianli Wang1, Mingxia Cao1, Charles Wood2, Rongtuan Lin3, Luwen Zhang4.   

Abstract

UNLABELLED: Kaposi's sarcoma (KS)-associated herpesvirus (KSHV) is a human gammaherpesvirus associated with several human malignancies. The replication and transcription activator (RTA) is necessary and sufficient for the switch from KSHV latency to lytic replication. Interleukin 1 (IL-1) is a major mediator for inflammation and plays an important role in both innate and adaptive immunity. Myeloid differentiation primary response gene 88 (MyD88) is an essential adaptor molecule for IL-1 as well as most Toll-like receptor signaling. In this study, we identified a novel mechanism by which KSHV interferes with host inflammation and immunity. KSHV RTA specifically reduces the steady-state protein levels of MyD88, and physiological levels of MyD88 are downregulated during KSHV lytic replication when RTA is expressed. The N-terminal region of RTA is required for the reduction of MyD88. Additional studies demonstrated that RTA targets MyD88 expression at the RNA level, inhibits RNA synthesis of MyD88, and may bind MyD88 RNA. Finally, RTA inhibits IL-1-mediated activation of NF-κB. Because IL-1 is abundant in the KS microenvironment and inhibits KSHV replication, this work may expand our understanding of how KSHV evades host inflammation and immunity for its survival in vivo. IMPORTANCE: MyD88 is an important molecule for IL-1-mediated inflammation and Toll-like receptor (TLR) signaling. This work shows that KSHV inhibits MyD88 expression through a novel mechanism. KSHV RTA may bind to MyD88 RNA, suppresses RNA synthesis of MyD88, and inhibits IL-1-mediated signaling. This work may expand our understanding of how KSHV evades host inflammation and immunity.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26468534      PMCID: PMC4702530          DOI: 10.1128/JVI.02342-15

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  55 in total

1.  Interferon regulatory factor 2 represses the Epstein-Barr virus BamHI Q latency promoter in type III latency.

Authors:  L Zhang; J S Pagano
Journal:  Mol Cell Biol       Date:  1999-04       Impact factor: 4.272

2.  The lytic switch protein of KSHV activates gene expression via functional interaction with RBP-Jkappa (CSL), the target of the Notch signaling pathway.

Authors:  Yuying Liang; Jean Chang; Stephen J Lynch; David M Lukac; Don Ganem
Journal:  Genes Dev       Date:  2002-08-01       Impact factor: 11.361

Review 3.  Cytokines and growth factors in the pathogenesis of AIDS-associated Kaposi's sarcoma.

Authors:  B Ensoli; G Barillari; R C Gallo
Journal:  Immunol Rev       Date:  1992-06       Impact factor: 12.988

4.  A transient heterochromatic state in Xist preempts X inactivation choice without RNA stabilization.

Authors:  Bryan K Sun; Aimée M Deaton; Jeannie T Lee
Journal:  Mol Cell       Date:  2006-03-03       Impact factor: 17.970

Review 5.  TLR signaling.

Authors:  Taro Kawai; Shizuo Akira
Journal:  Semin Immunol       Date:  2007-02-01       Impact factor: 11.130

6.  Kinetics of Kaposi's sarcoma-associated herpesvirus gene expression.

Authors:  R Sun; S F Lin; K Staskus; L Gradoville; E Grogan; A Haase; G Miller
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

7.  A Kaposi's sarcoma-associated herpesvirus protein that forms inhibitory complexes with type I interferon receptor subunits, Jak and STAT proteins, and blocks interferon-mediated signal transduction.

Authors:  Sabine A Bisson; Anne-Laure Page; Don Ganem
Journal:  J Virol       Date:  2009-03-11       Impact factor: 5.103

8.  Anti-oncogenic and oncogenic potentials of interferon regulatory factors-1 and -2.

Authors:  H Harada; M Kitagawa; N Tanaka; H Yamamoto; K Harada; M Ishihara; T Taniguchi
Journal:  Science       Date:  1993-02-12       Impact factor: 47.728

9.  Kaposi's sarcoma-associated herpesvirus RTA promotes degradation of the Hey1 repressor protein through the ubiquitin proteasome pathway.

Authors:  Faye Gould; Sally M Harrison; Eric W Hewitt; Adrian Whitehouse
Journal:  J Virol       Date:  2009-04-15       Impact factor: 5.103

10.  Functional analysis of a dominant negative mutation of interferon regulatory factor 5.

Authors:  Long Yang; Tiejun Zhao; Xiaoliu Shi; Peyman Nakhaei; Yunling Wang; Qiang Sun; John Hiscott; Rongtuan Lin
Journal:  PLoS One       Date:  2009-05-11       Impact factor: 3.240

View more
  12 in total

Review 1.  Kaposi sarcoma-associated herpesvirus: immunobiology, oncogenesis, and therapy.

Authors:  Dirk P Dittmer; Blossom Damania
Journal:  J Clin Invest       Date:  2016-09-01       Impact factor: 14.808

Review 2.  Activation and Evasion of Innate Immunity by Gammaherpesviruses.

Authors:  Philip T Lange; Maria C White; Blossom Damania
Journal:  J Mol Biol       Date:  2021-08-23       Impact factor: 5.469

Review 3.  Innate Immune Responses to Herpesvirus Infection.

Authors:  Christine M O'Connor; Ganes C Sen
Journal:  Cells       Date:  2021-08-18       Impact factor: 7.666

4.  MyD88 Regulates LPS-induced NF-ĸB/MAPK Cytokines and Promotes Inflammation and Malignancy in Colorectal Cancer Cells.

Authors:  Guangwei Zhu; Zhibin Cheng; Chunlin Lin; Robert M Hoffman; Yongjian Huang; Shree Ram Singh; Wei Zheng; Shugang Yang; Jianxin Ye
Journal:  Cancer Genomics Proteomics       Date:  2019 Nov-Dec       Impact factor: 4.069

5.  MyD88 mediates colorectal cancer cell proliferation, migration and invasion via NF‑κB/AP‑1 signaling pathway.

Authors:  Guangwei Zhu; Zhibin Cheng; Yongjian Huang; Wei Zheng; Shugang Yang; Chunlin Lin; Jianxin Ye
Journal:  Int J Mol Med       Date:  2019-10-31       Impact factor: 4.101

Review 6.  Toll-like receptor-mediated innate immunity against herpesviridae infection: a current perspective on viral infection signaling pathways.

Authors:  Wenjin Zheng; Qing Xu; Yiyuan Zhang; Xiaofei E; Wei Gao; Mogen Zhang; Weijie Zhai; Ronaldjit Singh Rajkumar; Zhijun Liu
Journal:  Virol J       Date:  2020-12-09       Impact factor: 4.099

7.  Antiviral activity of 20(R)-ginsenoside Rh2 against murine gammaherpesvirus.

Authors:  Soowon Kang; Kyungtaek Im; Geon Kim; Hyeyoung Min
Journal:  J Ginseng Res       Date:  2016-09-01       Impact factor: 6.060

Review 8.  Suppression of NF-κB Activity: A Viral Immune Evasion Mechanism.

Authors:  Liyao Deng; Qiurui Zeng; Mingshu Wang; Anchun Cheng; Renyong Jia; Shun Chen; Dekang Zhu; Mafeng Liu; Qiao Yang; Ying Wu; Xinxin Zhao; Shaqiu Zhang; Yunya Liu; Yanling Yu; Ling Zhang; Xiaoyue Chen
Journal:  Viruses       Date:  2018-08-04       Impact factor: 5.048

Review 9.  KSHV: Immune Modulation and Immunotherapy.

Authors:  Grant Broussard; Blossom Damania
Journal:  Front Immunol       Date:  2020-02-07       Impact factor: 7.561

Review 10.  Role of Interleukin-1 Family Members and Signaling Pathways in KSHV Pathogenesis.

Authors:  Lindsey Barrett; Jungang Chen; Lu Dai; Karlie Plaisance-Bonstaff; Luis Del Valle; Zhiqiang Qin
Journal:  Front Cell Infect Microbiol       Date:  2020-10-30       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.